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ABSTRACT: The tendency for crystallization during storage and
administration is the most considerable hurdle for poorly water-
soluble drugs formulated in the amorphous form. There is a need
to better detect often subtle and complex surface crystallization
phenomena and understand their influence on the critical quality
attribute of dissolution. In this study, the interplay between surface
crystallization of the amorphous form during storage and
dissolution testing, and its influence on dissolution behavior, is analyzed for the first time with multimodal nonlinear optical
imaging (coherent anti-Stokes Raman scattering (CARS) and sum frequency generation (SFG)). Complementary analyses are
provided with scanning electron microscopy, X-ray diffraction and infrared and Raman spectroscopies. Amorphous
indomethacin tablets were prepared and subjected to two different storage conditions (30 °C/23% RH and 30 °C/75% RH) for
various durations and then dissolution testing using a channel flow-through device. Trace levels of surface crystallinity
previously imaged with nonlinear optics after 1 or 2 days of storage did not significantly decrease dissolution and
supersaturation compared to the freshly prepared amorphous tablets while more extensive crystallization after longer storage
times did. Multimodal nonlinear optical imaging of the tablet surfaces after 15 min of dissolution revealed complex
crystallization behavior that was affected by both storage condition and time, with up to four crystalline polymorphs
simultaneously observed. In addition to the well-known α- and γ-forms, the less reported metastable ε- and η-forms were also
observed, with the ε-form being widely observed in samples that had retained significant surface amorphousness during storage.
This form was also prepared in the pure form and further characterized. Overall, this study demonstrates the potential value of
nonlinear optical imaging, together with more established solid-state analysis methods, to understand complex surface
crystallization behavior and its influence on drug dissolution during the development of amorphous drugs and dosage forms.
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1. INTRODUCTION
Conversion of the crystalline form of a drug into its amorphous
form is one of the most promising enabling formulation
approaches for the increasing number of poorly water-soluble
drug molecules. The amorphous form, despite its thermody-
namic physical instability and tendency for recrystallization, is
often considered, as it offers a considerable solubility advantage
over its crystalline counterpart.
In the early stages of amorphous drug development,
solubility and dissolution are investigated. Experimentally,
intrinsic dissolution tests ensure a constant surface area1 and
thus potentially enable the evaluation of solid-state effects,
while the particle size effects are minimized. In addition to the
conventional rotating disk apparatus, different flow-through
and channel flow systems have been developed. Theoretically,
the solubility and dissolution advantage of amorphous drugs
can be calculated on the basis of thermal properties. The
calculated increases in solubility and dissolution are generally
higher than those experimentally obtained.2 For instance, the
experimentally determined solubility advantage of amorphous
to crystalline γ-indomethacin is between 4.52 and 4.9,3 whereas
the predicted ratio at 25 °C is between 25 and 104.2 It is
believed that the driving force for dissolution can be predicted
fairly well based on the thermodynamic calculations and that
the experimentally determined values are often under-
estimated.2,3 One reason for underestimated experimental
solubility and dissolution results is surface crystallization to less
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soluble forms during dissolution (solution-mediated or direct
solid−solid). Furthermore, during administration, crystalliza-
tion of the amorphous form can also occur and lead to
insufficient concentration of dissolved drug molecules available
for absorption and a consequent lack of therapeutic effect. For
these reasons, it is important to detect and understand
crystallization processes during dissolution testing.
Coupling solid-state analysis with dissolution testing can
provide understanding of the surface solid-state phenomena
affecting the dissolution process. Glancing angle X-ray
diffraction (XRD) has been used to monitor surface
crystallization after dissolution of partially amorphous
indomethacin compacts as a function of tablet depth.4 Imaging
methods, such as polarized light microscopy (PLM) and ATR-
FTIR spectroscopic imaging,5 are also potentially attractive
choices. However, the solid-state specificity of PLM is limited,
and in the case of ATR-FTIR, the water complicates sampling
and, depending on the selected region or peak of interest, can
also interfere with analysis.5 Due to its insensitivity to water,
Raman spectroscopy has been used in situ to monitor solid-
state changes occurring during dissolution.6,7 However,
conventional Raman systems, including with Raman probes,
may not be sufficiently surface-specific to prevent the surface
signal being overwhelmed by the signal from the core of the
sample.6,7 In the case of a very thin crystalline layer forming on
the surface of the amorphous sample, even Raman microscopy
cannot always detect surface crystallinity.8 The relatively slow
imaging speed of conventional Raman microscopy contributes
to this challenge.
Nonlinear optical imaging, in particular involving coherent
anti-Stokes Raman scattering (CARS) or sum frequency
generation (SFG), is gaining interest in the solid-state analysis
of pharmaceutics.9 As well as offering rapid contactless
sampling with submicron lateral resolution, nonlinear analytical
methods are highly surface sensitive due to their being
inherently confocal, with the signal being generated only in the
focal volume of the overlapping lasers when phase matching
criteria are fulfilled. CARS is orders of magnitude faster than
conventional Raman microscopy (based on spontaneous
Raman scattering) and has been used to image crystal phase
transformations associated with the dissolution of pharma-
ceutical tablets,10,11 in particular, solution-mediated hydrate
formation.12 Sum frequency generation (SFG), including
second-harmonic generation (SHG), has proven powerful in
detecting trace levels of crystallinity.13−17 SFG can differentiate
amorphous from crystalline forms (as long as the crystals are
not centrosymmetric), as only noncentrosymmetric crystals
can generate a bulk SFG signal. However, SFG alone cannot
separate different crystals that belong to the same classification
in terms of centrosymmetry (although the magnitude of the
SFG signal may be different). Multimodal nonlinear imaging,
in which two or more nonlinear optical techniques are
combined, can provide more specific and reliable analysis
when the amorphous form and multiple polymorphs are
present. In our recent study,18 the synergistic use of
simultaneous CARS and SFG imaging allowed the distribution
of the amorphous form and crystalline forms of the drug
indomethacin to be imaged. The surface crystallization of the
amorphous indomethacin tablets during storage was also
imaged.18 Briefly, the tablets stored at lower humidity
crystallized predominately to the γ-indomethacin, whereas
the tablets stored at higher humidity crystallized mostly to the
α-form. Some small areas of the nondominant polymorph, not
detected with ATR-FTIR or Raman spectroscopies, were also
observed. Crystallization was also detected at an earlier stage
with multimodal nonlinear optics than with ATR-FTIR and
Raman spectroscopies.
Indomethacin is a widely studied drug with respect to its
solid-state behavior and has been reported to exist in several
polymorphic forms: α, β, γ, δ, ε, ζ, η, τ, as well as an unnamed
form.19−24 Some of these forms have only been observed in
quite specific conditions; for example, the ζ- and η-forms were
detected after exposure of amorphous particles to pH 1.2
buffer solution, while the τ form has been observed in
semicrystalline dispersions. The β form was later confirmed to
be a benzene solvate.25 The crystal structures have been
reported only for the α- and γ-polymorphs, although the
powder XRD profiles for the other forms except ε have been
published. The ε-form is less well-characterized than the other
polymorphs due to stability-related measurement difficulties.23
In addition to these crystalline forms, the amorphous form of
indomethacin has been widely studied. Numerous studies have
independently evaluated the dissolution26−28 and storage-
induced29−31 solid-state transformations of the amorphous
form of indomethacin. However, studies exploring the
relationship between the partial (surface) crystallization
induced by storage and dissolution behavior are limited.32
In this study, multimodal nonlinear imaging (CARS and
SFG), together with XRD and ATR-FTIR spectroscopy, were
utilized to investigate the relationship between surface
crystallization of amorphous indomethacin tablets, during
both storage and dissolution, and dissolution behavior. Of
particular interest was whether very early stage crystallization
during storage, as detected earlier with nonlinear imaging,18
would affect surface crystallization during dissolution as well as
dissolution behavior. The complex surface crystallization
behavior of the freshly prepared and stored samples, including
the simultaneous appearance of multiple solid-state forms and
their distribution, was investigated.
2. MATERIALS AND METHODS
2.1. Sample Preparation. Amorphous indomethacin was
prepared from the γ-form (Orion, Finland) by cooling the melt
to room temperature.33 Once solidified, the sample was kept in
a desiccator with phosphorus pentoxide for 30 min, after which
it was pulverized and compressed into tablets with a benchtop
single punch press (Specac, UK). Flat-faced tablets were
compressed with the same pressure of 1 ton and a dwell time
of 30 s. The tablets weighed 300 ± 5 mg and had a diameter of
13 mm and a height of 2 mm. The same side of the tablet
(upper side in the tablet press) was exposed to the dissolution
medium and analyzed in all measurements. Freshly prepared
amorphous indomethacin tablets were analyzed within a
couple of hours and denoted as 0-day samples. To promote
crystallization, the tablets were placed in open glass vials and
stored at 30 °C at lower (23%) or higher (75%) relative
humidity, obtained by using saturated salt solutions of
potassium acetate and sodium chloride, respectively.
The γ-form (with a centrosymmetric P1̅ crystal structure)
was used as received. The α-indomethacin form (with a
noncentrosymmetric P21 crystal structure) was obtained by
antisolvent precipitation with Milli-Q water from a warm
ethanol solution prepared from γ-indomethacin.25 The ε-form
of indomethacin was prepared from a suspension of
amorphous indomethacin in pH 6.8 phosphate buffer.23,34
The δ-form was prepared from indomethacin methanolate.22
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Tablets composed of pure α-indomethacin were prepared in a
similar manner as described for amorphous indomethacin.
Attempts in making tablets composed from pure γ-
indomethacin resulted in lamination and breakage in the
dissolution cell sample cavity. Therefore, the initially
amorphous tablets stored for 5 months at 30 °C/23% RH
were used as pure γ-indomethacin tablets. Complete
crystallization to the γ-indomethacin over a 5-month period
was confirmed with XRD, differential scanning calorimetry
(DSC), and FTIR.
2.2. Intrinsic Dissolution Testing. Freshly prepared
amorphous tablets, as well as those stored for 1, 2, 7, or 22
days were subjected to dissolution testing in a custom-built
channel flow system. The experimental setup was similar to
that described by Peltonen et al.35 The tablets were inserted in
the cavity in the middle of the cell such that only one surface
was flushed with fresh dissolution medium. Tablets and the
cavity had a diameter of 13 mm and thus a constant surface
area of 1.33 cm2. The peristaltic pump (Watson Marlow
505U), channel flow cell, and reservoir with dissolution
medium were connected with silicone tubing in an open loop
manner. This ensured the constant availability of fresh buffer
and maintenance of true sink conditions. The flow was kept
constant at 9 mL/min.36 This rate has earlier been found to
simulate the (axial) velocity of the intestine best.37 Solution
samples were collected downstream every 30 s for the first 5
min and then in 1 min intervals until 30 min. The absorbance
of unfiltered samples33 was measured at 318 nm1 with a
1600PC UV−Vis spectrophotometer (VWR, China). Every
dissolution experiment was performed at least in triplicate.
Phosphate buffer with a pH of 6.8 was used as the aqueous
medium. A series of standard solutions of indomethacin in pH
6.8 phosphate buffer with concentrations ranging from 0.5 to
40 μg/mL was used to construct a calibration curve for
quantification. As the tablets remained whole at the end of the
experiment, the tablet surface exposed to the liquid medium
could subsequently be further analyzed. All solid-state
measurements on tablets subjected to dissolution testing
were performed after 15 min of dissolution testing. Prior to
solid-state analysis, the tablets’ surfaces were blotted with lens
cleaning tissue paper and removed from the channel flow cell.
2.3. Scanning Electron Microscopy (SEM). Surface
sections of the tablets were mounted on double-sided carbon
tape and sputter coated with platinum. The micrographs were
obtained with a FEI Quanta 250 field emission gun SEM (FEI,
Hillsboro, USA) microscope using a high vacuum and a
voltage of 10 kV.
2.4. X-ray Diffractometry (XRD). Diffractograms were
collected in reflection mode using a Malvern Panalytical
Empyrian (PANalytical B.V. Almelo, The Netherlands)
instrument with Cu Kα1 radiation (λ = 1.5406) and a
divergence slit of 0.76 mm. The generator voltage was 45 kV,
and the tube current 40 mA. Data were collected in a 2θ scan
range of 5 to 50° with a step size of 0.013°. The tablets were
rotated during the measurements.
2.5. Fourier Transform Infrared Spectroscopy (FTIR).
FTIR analysis was performed using a single-reflection MIRacle
attenuated total reflectance (ATR) crystal (Pike Technologies,
Wisconsin, USA) with a Vertex 70 spectrometer (Bruker
Optics, Ettlingen, Germany). Measurements were collected
using OPUS 5.5 (Bruker Optics, Ettlingen, Germany) software.
Each spectrum consisted of an average of 256 scans with a
spectral resolution of 4 cm−1. The obtained spectra were
standard normal variance (SNV) corrected prior to principal
component analysis (PCA) in the spectral range of 1400−1800
cm−1 using Simca software V10.5 (Umetrics, Umea, Sweden).
2.6. Multimodal Nonlinear Optical Imaging. Multi-
modal nonlinear imaging was performed with a Leica SP8
CARS microscope (Leica, Wetzlar, Germany). The CARS
excitation source was a solid-state Nd:YVO4 laser. The Stokes
(fundamental) laser line at 1064.5 nm was temporally and
spatially overlapped with the pump/probe beam. The wave-
length of the pump line was tuned by an optical parametric
oscillator (OPO). Combined incident beams were directed
into an inverted microscope with an IR corrected 25×, 0.95
NA water immersion objective. The signal was collected in epi
(backscattered) mode. For narrowband (single line) imaging
and CARS spectral scans, photomultiplier tube (PMT)
detectors were used, while for the second-order nonlinear
spectra (including SFG), hybrid detectors (HyD) were used.
Bright field images were collected in reflection mode using a
633 nm HeNe laser and PMT detector in the 623−643 nm
range. The step size for the CARS spectral measurements was
1 nm (corresponding to a spectral resolution of approximately
12 cm−1), whereas for the second-order spectral scans, the step
size was 10 nm.
Three imaging modalities were used for the same field of
view: (i) CARS spectral scans in the range of 1413−1800
cm−1, (ii) second-order nonlinear spectral scans in the range of
400 to 700 nm, and (iii) a combination of narrowband CARS
and SFG imaging. The combination images represent overlays
of three channels: a single CARS line at 1701 cm−1 in red (γ-
indomethacin), a single CARS line at 1676 cm−1 in blue
(amorphous indomethacin), and a third channel representing
the SFG signal (all noncentrosymmetric crystals). Potential
two-photon excited fluorescence background signal interfer-
ence in the narrowband images was minimized by subtracting
the images obtained by one-laser excitation (pump laser only).
Images represent the maximum projections of single-plane
optical images at 2 μm steps in the z-direction. This step size
was selected, as the instrument axial resolution is 2.5 μm. The
total depth of the maximum projection images obtained in this
manner was in the range of 20 to 52 μm. The lateral image size
was 512 × 512 pixels covering a 465 × 465 μm area with
images being collected with a line average of 4 and pixel dwell
time of 1.2 μs. At least three different spots of each tablet were
analyzed. To resolve SFG signal originating from different
SFG-active polymorphs, the characteristic CARS peaks from
the same regions were analyzed using Fiji ImageJ 1.51. False
coloring (green and yellow) was assigned based on the relative
intensity ratios of the CARS peaks at 1652 and 1676 cm−1. The
regions having SFG activity and a CARS peak at 1652 cm−1
characteristic for α-indomethacin were colored green, while
those having SFG activity and a CARS peak at 1676 cm−1
characteristic for ε-indomethacin were colored yellow.
3. RESULTS
3.1. Dissolution Behavior. 3.1.1. Pure Amorphous and
Reference Crystalline Forms. As shown in Figure 1, the
maximum dissolved concentration for the 0-day sample was
reached after 2 min of dissolution testing and was around 12-
fold higher than that of the reference γ-crystalline form of
indomethacin, which stabilized at around 2 μg/mL. Super-
saturation was followed by a concentration drop, indicating
solution-mediated crystallization. The crystalline α-form
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exhibited a slightly increased concentration compared to the γ-
form (around 3 μg/mL).
Crystallization on the surface of a dissolving tablet can
increase the effective surface area available for dissolution.38
Such an effect could be of greater influence for samples with
higher levels of crystallization where the increase in surface
area is greater. This can potentially explain why the dissolution
profiles were not approaching those of the reference crystalline
forms toward the end of the measurements. Another potential
reason is that metastable polymorphs, more soluble than the α-
or γ-forms, were crystallizing on the tablet surface.
3.1.2. Stored Samples. Amorphous indomethacin samples
were kept in controlled storage conditions for 22 days, and
their dissolution properties were periodically monitored. The
largest differences between the samples in Figure 1 can be seen
within the first 15 min. The maximum drug concentrations
decreased upon increased storage time. At the beginning of the
experiments, the dissolution profiles of the 1-day and 2-day
samples were still largely similar to that of the freshly prepared
tablets and faster than those of the samples stored for longer
periods, although the 2-day sample stored at 30 °C/75% RH
exhibited a slightly lower maximum concentration. The most
pronounced effects of storage time and conditions can first be
seen at 7 days of storage, when the maximum and subsequent
concentrations were substantially lower. This was especially the
case for tablets stored at 30 °C/23% RH, whose achieved
concentrations were around two times lower than those of the
tablets stored at 30 °C/75% RH. The dissolution profiles of
the 22-day tablets stored at 30 °C/23% RH closely resembled
those of the reference γ-form. The profiles of the 22-day tablets
stored at 30 °C/75% RH were between or similar to those of
the reference α- and γ-crystalline forms.
3.2. Visual Appearance. A change in surface color upon
dissolution, indicating crystallization, was observed for many of
the samples. This was visible especially when tablets were
broken: a thin white layer that had formed on the surface
exposed to the dissolution medium was clearly observed. The
rest of the tablet remained yellow, which is characteristic of the
amorphous form. A dissolution-induced change was less
pronounced or not present for the samples stored for longer
periods of time (7 and 22 days) at lower humidity, as they
Figure 1. Dissolution profiles (drug release over time) for samples
stored at (a) 30 °C/23% RH and (b) 30 °C/75% RH. Profiles of the
pure amorphous tablet (day 0) and reference crystalline γ- and α-
forms are shown for comparison. Profiles are generated with mean
values of a minimum of three measurements. Error bars represent plus
one standard deviation.
Figure 2. SEM micrographs of an amorphous indomethacin tablet (day 0, first column) and tablets stored for 1, 2, 7, and 22 days (from left to
right) at 30 °C/23% RH before dissolution testing (top row). SEM images of the tablets prepared and stored in the same manner after 15 min of
intrinsic dissolution testing (bottom row).
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were already relatively white and presumably relatively
crystalline throughout the tablet prior to dissolution testing.
3.3. Surface Morphology. The morphology of fresh and
stored tablet surfaces after 15 min of dissolution testing was
compared to the surfaces before dissolution testing using SEM
(Figures 2 and 3). The surface of the freshly prepared tablet
previously confirmed as amorphous was quite smooth.18
Surfaces of tablets stored at 30 °C/23% RH prior to
dissolution featured plate-like particles, and their surface
coverage increased over time. The storage-induced changes
in surface morphology were slower for the tablets stored at 30
°C/75% RH, and many observed particles on these tablets had
needle-like morphology.18
After 15 min of dissolution, the surface of the 0-day tablet
had changed; crystal-like particles were observed in addition to
smooth-looking areas. The 1-day samples after dissolution
were similar to the freshly prepared samples after dissolution
and also had some largely smooth regions. For both storage
conditions, the 2-day samples had more needle-shaped
particles after dissolution. The needles were usually 1−2 μm
in size, with the largest observed needles being 40 μm long.
The morphologies of the samples stored for the same times at
different storage conditions after dissolution testing became
strikingly different at day 7. The surfaces of tablets stored at 30
°C/23% RH was covered with plate-like particles, mostly 1−2
μm in size, with some up to about 5 μm. A few needle-shaped
structures were also observed, but their number was
considerably lower. In contrast, the surfaces of tablets stored
at 30 °C/75% RH had many needle-like particles with some
arranged in a spiral-like morphology (Figure 3, day 7 after
dissolution). Most of the needles were between 5 and 10 μm
long, although the largest was 100 μm in length. This
difference for the two different storage conditions remained
pronounced for the 22-day samples after dissolution. The
largest observed plate-like particles for samples stored at lower
humidity were 20 μm. Needle shaped particles for samples
stored at higher humidity appeared more fused together over
larger areas, and the majority of the individual particles were
about 5 μm in length.
Crystals of γ-indomethacin generally have a plate-like
morphology, whereas α-indomethacin crystals are needle-like
with growth in the form of fibrous/spherulitic structures.39
While the SEM images are suggestive of storage time- and
condition-dependent crystallization for at least these two forms
during dissolution, more specific solid-state analysis was
performed with multimodal nonlinear optical imaging, together
with XRD and ATR-FTIR spectroscopy.
3.4. Solid-State Analysis. Solid-state analysis was
performed off-line by XRD, ATR-FTIR, and CARS/SFG
upon 15 min of dissolution.
3.4.1. Freshly Prepared Amorphous Indomethacin (Day
0). Prior to dissolution, the freshly prepared indomethacin
tablet was amorphous according to XRD (Figure 4). Even
though any potential remaining surface moisture after tablet
blotting could partially attenuate the XRD signal, after 15 min
of dissolution testing, we were able to see the appearance of
two small diffraction peaks at 15.8 and 18.8° above the
amorphous halo. This indicated partial crystallization. These
two peaks did not correspond to those of previously published
X-ray diffractograms of indomethacin polymorphs (α, γ,19,25
Figure 3. SEM micrographs of an amorphous indomethacin tablet (day 0, first column) and tablets stored for 1, 2, 7, and 22 days (from left to
right) at 30 °C/75% RH before dissolution testing (top row). SEM images of the tablets prepared and stored in the same manner after 15 min of
intrinsic dissolution testing (bottom row).
Figure 4. XRD diffractograms of tablets before and after 15 min of
dissolution testing: (a) storage at 30 °C/23% RH and (b) storage at
30 °C/75% RH. Diffractograms of the α-, γ-, and ε-forms of
indomethacin are shown for comparison, and some of their
characteristic peaks are marked in green, red, and yellow, respectively.
The ε-form was measured in transmission mode using a powder,
while the α- and γ-forms were measured in reflection with tablets.
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δ,22 ζ, η,23 and τ24). The ε-form of indomethacin was also
prepared in the present study, and its XRD pattern is presented
and attributed to this form for the first time (Figure 4). The
two peaks from the tablet after dissolution testing correspond
to this diffraction pattern of the ε-form (marked in yellow in
Figure 4). The diffractogram of the ε-form also had
considerable similarity with the unnamed form of indometha-
cin reported by Lin.21
ATR-FTIR spectroscopy, which is more surface-specific than
XRPD (sampling depth limited to approximately 1 to 2 μm)
was also performed (Figure S1). Based on the PCA of the
spectra (Figure 5), the same samples (after 15 min of
dissolution testing) were most similar to the amorphous form
even though their score values slightly approached that of the
crystalline ε-form. This indicates some limited surface coverage
with the ε-form.
To obtain more precise information about the dissolution-
induced surface distribution of the ε-form and any other
potential minority species not detected with XRD and ATR-
FTIR, multimodal nonlinear imaging was performed. No SFG
or CARS signals indicative of crystallization were detected on
the surface of the freshly prepared amorphous tablets prior to
dissolution testing (Figures 6a and 7a), further confirming
their amorphous nature. SFG has previously been shown to be
very sensitive in detecting compression-induced crystallization
to polymorphs with a noncentrosymmetric structure.16 In
contrast, signs of extensive crystallization after dissolution
testing could be seen in a strong SFG signal (in yellow in
Figures 6b and 7b). As these signals are only generated in the
absence of centrosymmetry (amorphous forms do not fulfill
this criterion but noncentrosymmetric crystals do), their
presence was a definite sign of the initially amorphous tablet
surface crystallizing during dissolution. The CARS spectral
scans of the same area of view provided further insights into
the polymorphism. The spectra from the SFG-active regions
featured peaks at 1579, 1615, and 1676 cm−1 (Figures 6d and
7d), which correspond to the reference CARS spectrum of the
ε-form of indomethacin. No other minority species were
detected.
3.4.2. Tablets after Storage at Lower Humidity (30 °C/
23% RH). XRD analysis of the 1-day tablet stored at lower
humidity prior to dissolution testing showed only an
amorphous halo (Figure 4). After 15 min of dissolution,
however, two small diffraction peaks (at 15.8 and 18.8° marked
in yellow) above the amorphous halo could be observed. These
peaks corresponded to the ε-form of indomethacin. For the 2-,
7-, and 22-day samples, almost no differences between the
diffraction patterns for the corresponding before and after
dissolution samples were observed. The 2-day samples
exhibited an amorphous halo with some characteristic
diffraction peaks of γ-indomethacin. The amorphous halo
was not observable for the 7- and 22-day samples, with the
diffractograms suggesting they were composed exclusively of γ-
indomethacin already prior to dissolution.
The ATR-FTIR spectra of the tablet surfaces after storage at
lower humidity (before dissolution) confirmed crystallization
to the γ-form of indomethacin previously reported after 5 days
of storage.18 The ATR-FTIR spectra of the tablets upon
dissolution were consistent with crystallization to the ε- and γ-
forms observed with XRD (Figure S1). In the PCA scores plot
(Figure 5), the post-dissolution tablets stored at lower
humidity (marked with squares) gradually moved away from
the amorphous and ε-forms and approached the γ-form as
storage time increased. Thus, a post-dissolution trend from the
ε- to γ-form as a function of storage time was observed.
Nonlinear optical imaging allowed a more detailed analysis
of the surface crystallization behavior and distribution of the
solid-state forms. Unlike for the freshly prepared samples,
CARS spectra characteristic of γ-indomethacin were extracted
from the images of all samples stored at lower humidity and
the corresponding samples that underwent dissolution testing
(Figure 6e). Thus, the spectra confirmed γ-indomethacin
crystals after 15 min of dissolution as early as after 1 day of
storage (Figure 6b), and a few γ crystals were also observed
predissolution.18 This crystallization to the γ-form at day 1,
both with the pre and postdissolution samples, was not
detectable with the XRD and ATR-FTIR setups used. The
increase in the surface area covered with γ-indomethacin
crystals (in red) can be seen in images of tablets stored for
increasing amounts of time both before and after dissolution.
The presence of the SFG-active ε-form with characteristic
CARS peaks at 1579, 1615, and 1676 cm−1 (Figure 6d) was
also observed for 1-day samples’ post-dissolution (but not
before dissolution). Unlike XRD and ATR-FTIR, with which
the ε-indomethacin was detected only at day 1 of post-
dissolution, areas covered with the ε-form were observed with
nonlinear imaging for all the samples stored at lower humidity
(including 0-day) except for the 22-day sample. The areas
covered with the ε-form post-dissolution decreased over
storage time, while the γ-indomethacin coverage increased.
Relatively large amorphous regions could still be seen on day 2,
Figure 5. PCA scores plot of the ATR-FTIR spectra of the
amorphous (day 0) and all stored samples after 15 min of dissolution
testing (a); loadings and reference IR spectra of different solid-state
forms of indomethacin (b).
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whereas from 7 days onward, they were notably decreased/
absent.
Solid-state-specific visualization of tablet surfaces with
nonlinear imaging in addition revealed some specific
distribution patterns. This was most apparent with cracks
present on the tablet surfaces at days 1 and 2crystallization
to the ε-form was concentrated in the vicinity of these cracks.
3.4.3. Tablets after Storage at Higher Humidity (30 °C/
75% RH). All samples stored at higher humidity, both before
and after dissolution, were at least partially amorphous
according to XRD (Figure 4). An amorphous halo
characterized the 1-day sample both prior and subsequent to
dissolution. The 2-, 7-, and 22-day samples had some γ-
indomethacin diffraction peaks, while the 7- and 22-day
samples also exhibited diffraction peaks characteristic of α-
indomethacin.
Crystallization to the α-form of indomethacin after 22 days
of storage at higher humidity (before dissolution) was
confirmed with ATR-FTIR spectroscopy previously.18 As can
be seen from the PCA scores plot of the ATR-FTIR spectra,
the 1-, 7-, and 22-day tablets stored at higher humidity that
underwent dissolution testing (marked with circles in Figure 5)
were mostly located between the reference solid-state forms of
indomethacin, indicating that multiple forms were present
simultaneously. The 2-day sample, however, was similar to ε-
indomethacin.
Multiple polymorphs were simultaneously detected with
multimodal CARS and SFG imaging. After storage and prior to
dissolution, crystallization to α-indomethacin was predom-
inantly observed at higher humidity. This was accompanied by
some traces of the γ-form (Figure 7a).18 Upon dissolution, in
contrast to XRD and ATR-FTIR, crystallization was evident for
the 1-day sample as seen by the strong SFG signals in yellow
(Figure 7b). At days 1 and 2 after dissolution, the majority of
the observed crystals (in yellow) were 2−3 μm in size. With
the samples stored for 7 and 22 days after dissolution, the
crystalline areas appeared slightly larger, with individual
crystals (in green) equal to or exceeding 10 μm. The CARS
spectra indicate that there were five solid-state forms after
dissolution testing. Similar to the samples stored at lower
Figure 6. CARS and SFG overlay images of samples stored at 30 °C/23% RH before (a) and after (b) 15 min of dissolution testing at pH 6.8.
CARS spectra in the range of 1413−1800 cm−1 from selected regions marked by arrows plotted with reference spectra of amorphous, ε-, and γ-
indomethacin (c−e). Overlay images (a, b) represent overlays of three channels: single CARS line at 1701 cm−1 in red (γ-indomethacin), single
CARS line at 1676 cm−1 in blue (amorphous indomethacin), and a third channel representing the SFG signal (all noncentrosymmetric crystals) in
green and yellow. The separation between green and yellow regions is based on the intensity ratios of CARS peaks at 1652 and 1676 cm−1 so that
the regions having SFG activity and a CARS peak at 1652 cm−1 are colored green (α-indomethacin), and the regions having SFG activity and a
CARS peak at 1676 cm−1 are colored yellow (ε-indomethacin). Panel (a) has been reprinted with permission from Novakovic et al.18 Copyright
2017 American Chemical Society. am = amorphous.
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humidity, the areas with characteristic CARS peaks at 1579,
1615, and 1676 cm−1 and SFG activity assigned to the ε-
indomethacin were observed for all the postdissolution
samples stored at higher humidity except for day 22 (Figure
7d). CARS spectra of α-indomethacin were observed from 2
days of storage onward (Figure 7e). Traces of the α-form were
also detected for the 1-day sample (Figure S2). The presence
of γ-indomethacin was confirmed in all stored samples after
dissolution testing (Figure 7f). Interestingly, the regions
covered with the γ-form were largest after 22 days of storage.
This finding is consistent with the XRD data, where the strong
peaks of the γ-form were observed in addition to the less
intense peaks corresponding to α-indomethacin (Figure 4b).
Areas having SFG activity and two strong sharp CARS peaks
at 1591 and 1640 cm−1 were clearly observed after dissolution
only on day 7 (Figure S3). These areas were found only in
traces. Based on the Raman spectra of indomethacin
polymorphs available in the literature,23,24 it is likely that this
polymorph is the η-form (with benzoyl CO stretching at
1642 cm−1 in the Raman spectra23).
3.4.4. Reference Raman and CARS Spectra. For reference,
CARS and Raman spectra of many of the different solid-state
forms of indomethacin are provided. Figure 8 shows the CARS
spectra of the γ-, α-, δ-, amorphous, ε-, and η-indomethacin
forms as well as the Raman spectra of these forms plus the ζ-
form. As the CARS and Raman spectral features arise from the
same molecular vibrations, they are uniquely related to one
another.18,40 Carbonyl stretching of the carboxylic acid and
benzoyl CO groups of indomethacin feature solid-state-
specific bands between 1500 and 1800 cm−1. The CARS and
Raman spectra for each solid-state form match one another.
Detailed FTIR and Raman band assignments have been
provided elsewhere.23,41 The lower spectral resolution of the
CARS spectra compared to the Raman spectra explains why
some smaller peaks or shoulders visible in the Raman spectra
disappear or are merged into larger peaks in the CARS spectra.
4. DISCUSSION
The concentration versus time dissolution profiles for the
freshly prepared amorphous samples show behavior typical of
amorphous indomethacin with different stages able to be
identified.8,27 As the dissolution rate is directly proportional to
the solubility of the drug (for a constant surface area), the
solubility of the solid-state form at the surface of the compact
dictates the release rate. Thus, after supersaturation is achieved
and the solution-mediated crystallization covers the exposed
Figure 7. CARS and SFG overlay images of samples stored at 30 °C/75% RH before (a) and after 15 min of dissolution testing at pH 6.8 (b).
CARS spectra in the range of 1413−1800 cm−1 from selected regions marked by arrows (c−f) plotted with reference spectra of amorphous, ε-, α-,
and γ-indomethacin. Overlay images (a, b) represent overlays of three channels: single CARS line at 1701 cm−1 in red (γ-indomethacin), single
CARS line at 1676 cm−1 in blue (amorphous indomethacin), and a third channel representing the SFG signal (all noncentrosymmetric crystals) in
green and yellow. The separation between green and yellow regions is based on the intensity ratios of CARS peaks at 1652 and 1676 cm−1 so that
the regions having SFG activity and the CARS peak at 1652 cm−1 are colored green (α-indomethacin), and the regions having SFG activity and
CARS peak at 1676 cm−1 are colored yellow (ε-indomethacin). Panel (a) has been reprinted with permission from Novakovic et al.18 Copyright
2017 American Chemical Society. am = amorphous.
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tablet surface, the intrinsic dissolution rate decreased.7 The
relatively large variability between the replicates for partially
amorphous samples as observed in this study has been
observed before.4 This has been attributed to the differences in
tablet microstructure and preferred orientation effects. Batch-
to-batch variation of dissolution behavior of an amorphous
formulation of tacrolimus, due to different crystallization
kinetics, has also been reported.42
The decrease in supersaturated concentrations of the stored
samples compared to the pure amorphous indomethacin
indicates that retardation of dissolution is induced by
crystallization during storage. In our previous study,18 early
stage crystallization during storage was detected with nonlinear
imaging already at days 1 and 2, which was at an earlier stage
than with ATR-FTIR and Raman microscopy. Here, we have
shown that this very early stage crystallization does not
significantly affect the dissolution performance with these
samples, as the final concentrations were similar for 0-, 1-, and
2-day samples at both storage conditions. Early stage
crystallization could, however, be important and reduce drug
dissolution in other samples or dissolution conditions, if these
crystals were to act as seeds and promote solution-mediated
growth of less soluble solid-state forms.
The crystallization of freshly prepared amorphous indome-
thacin upon dissolution has been quite extensively studied.
Conversion to the α-polymorph during dissolution has
previously been observed with Raman26 and in situ Raman
spectroscopy.6,27 The α-form has been found to dominate in
precipitates from supersaturated amorphous indomethacin
solutions formed in ethanol/water at 37 °C observed by Sun
et al.,43 while the γ-polymorph was observed with indometha-
cin/PVP solid dispersions in the same study. While studying
the dissolution of quench-cooled amorphous indomethacin in
water in a flow-through cell at room temperature, Greco and
Bogner8 detected three polymorphs with confocal Raman
microscopy: the α- and γ-polymorphs as well as an unidentified
form with a sharp peak at 1670 cm−1. The form characterized
by the peak at 1670 cm−1 has also been observed with Raman
spectroscopy mapping at different dissolution time points by
Tres et al.33 The peak was observed for extrudates of
indomethacin with copovidone in a dissolution flow cell at
25 °C in pH 6.8 phosphate buffer.33 While studying aqueous
suspensions prepared with amorphous indomethacin at room
temperature and a pH of 6.8, Surwase et al.23 identified
indirect conversion of amorphous indomethacin to the α-
polymorph via the form they denoted as the ε-form (observed
after 5 min) using ATR-FTIR spectroscopy. At a lower
temperature (5 °C) at both pH 6.8 and 1.2, the α-form only
became dominant after several sequential transformations
involving the ε-, ζ-, and η-forms.
Figure 8. CARS (solid lines) and Raman (dotted lines) spectra of
indomethacin solid-state forms. Raman spectra (except for the ε-
form) are reproduced with permission from ref 23. The CARS
spectral resolution is 12 cm−1, while the Raman spectral resolution is
4 cm−1. All CARS spectra are measured from the prepared reference
forms, except for the spectrum of the η-form, which was recorded at
the tablet surface. Polymorphs marked with asterisk are SFG-active.
Table 1. Overview of the Observed Solid-State Forms of Indomethacin before and after 15 min of Dissolution
sample solid state forms
XRD ATR-FTIRa CARS/SFG
before after before18 after before18 after
Day 0 amb am, ε am am, ε (traces) am am, ε
30 °C/23% RH
Day 1 am am, ε am am, ε (traces) am, γ am, ε, γ
Day 2 am, γ am, γ am, γ γ am, γ, α (traces) am, ε, γ
Day 7 γ γ γ γ γ, α ε, γ
Day 22 γ γ γ γ γ, α (traces) γ
30 °C/75% RH
Day 1 am am am am am, α (traces) am, ε, γ, α (traces)
Day 2 am, γ am, γ, ε am, γ ε am, α, γ (traces) am, ε, γ, α
Day 7 am, γ, α am, γ, α am, γ am, ε, γ am, α, γ (traces) am, ε, γ, α, η (traces)
Day 22 am, γ, α am, γ, α am, α am, γ am, α, γ (traces) am, γ, α
aTentative assignments based on IR spectra and PCA. bam = amorphous.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.8b00840
Mol. Pharmaceutics 2018, 15, 5361−5373
5369
The results of the present study for day 0 are largely
consistent with these studies. However, we observed surface
crystallization only to the ε-form of indomethacin, most likely
due to the earlier time point of dissolution (15 min) when
solid-state analysis was performed. As confirmed by Surwase et
al.,23 at pH 6.8 and room temperature (25 °C), the conversion
of the amorphous to α-form can be via the metastable ε-
polymorph. If the solid-state analysis in the present study had
been performed at a later time point, it is likely that the α-form
would have been predominantly observed.
The observed ε-form was prepared in pure form and further
characterized in this study. Surwase et al.23 and Koranne et
al.34 reported the IR spectra of the ε-polymorph. We believe
that the Raman peak at around 1670 cm−1 observed in earlier
dissolution studies with amorphous indomethacin8,33 was also
due to formation of the ε-form. In the present study, this
polymorph was confirmed by ATR-FTIR and further
characterized by XRD, Raman, CARS, and SFG.
The storage time affected the crystallization and dissolution
behavior at both studied storage conditions. The influence of
crystallization to the γ-polymorph during storage at 25 °C/0%
RH on dissolution was studied by Greco and Bogner.8 The
dissolution in water of amorphous indomethacin prepared by
quench-cooling the melt and stored for 1 week resulted in the
presence of three forms identified by confocal Raman
microscopy: γ, the unidentified form with a peak at 1670
cm−1 (which we attribute to the ε-form), and, at the end of
experiments, the α-form. Samples having a higher percentage
of crystallinity stored for 3 weeks showed two forms: γ and the
form with the Raman peak at 1670 cm−1, while the 6-week
sample showed only the presence of the γ-form. Though the
time scales and storage conditions are different, the findings
exhibit the same trend as our observations at 30 °C/23% RH;
the 1-day and 2-day samples had similar crystallization
behavior to Greco and Bogner’s 1-week samples, and the 22-
day samples corresponded to Greco and Bogner’s 6-week
sample.
The solid-state results obtained with different analytical
techniques are summarized in Table 1. Multiple polymorphs
were detected simultaneously with all the used techniques. Of
all the analytical techniques used, the combination of CARS
and SFG proved to be the most potent in detecting especially
the ε- and α-forms of indomethacin after dissolution.
Furthermore, nonlinear imaging was especially capable of
detecting multiple solid-state forms simultaneously including
those present only in traces, including the η-form. For instance,
the amorphous form together with four indomethacin
polymorphs (ε, γ, α, η) were visualized on the surface of a
7-day tablet stored at 30 °C/75% RH after dissolution.
Storage at higher humidity yielded a larger number of
observed metastable forms upon dissolution. Surface crystal-
lization in the solid state is now relatively well estab-
lished.18,30,44−46 In the current study, surface crystallization
to the ε- and η-forms was observed only upon dissolution,
indicating the process was solution-mediated.
SFG analysis revealed that, as well as the α-form, the ε-, η-,
and δ-forms of indomethacin have noncentrosymmetric
crystalline structures, based on their SFG activity. As the
crystal structures of the ε-, η-, and δ-forms have not yet been
solved, this provides at least some indication of their possible
space groups. In addition to offering such solid-state structure
information, multimodal nonlinear imaging involving both
CARS and SFG provided greater confidence in resolving these
polymorphs. SHG imaging has been used independently in
stability and dissolution testing of amorphous drugs and their
formulations17,47 and was shown to have a large detection
range, with a detection limit well-below that for routinely used
methods such as DSC or XRPD. These studies however
involved the crystallization of the amorphous form into one
noncentrosymmetric (SHG-/SFG-active) crystalline form.
Here, the SFG analysis is further enriched with vibrational
spectroscopic characterization provided by CARS, which
enabled identification of different crystal forms of indometha-
cin that could not have been resolved using SFG only.
The existence of different solid-state forms simultaneously
makes some time points more difficult to interpret with the
employed nonspatially resolved techniques of XRD and ATR-
FTIR (combined with PCA). The XRD diffractograms and
ATR-FTIR spectra (together with PCA scores) contain
contributions from all present solid-state forms. The highly
spatially resolved pixel-by-pixel nature of multimodal nonlinear
imaging resulted in generally solid-state resolved signals, and
minority polymorphs present were efficiently detected, in
addition to the main polymorphic forms observed by XRD and
ATR-FTIR.
The surface sensitivity of nonlinear optical imaging,
combined with noncontact sampling, was important as
highlighted by the samples stored at 30 °C/75% RH that
exhibited dissolution-induced surface formation of the ε-form
according to the nonlinear optical imaging results. This signal
was not always apparent with XRD or ATR-FTIR spectros-
copy. It is likely that the surface layer of these crystals could be
so thin that the amorphous indomethacin signal from within
the tablet overwhelmed the XRD signal, while the compression
on the ATR-FTIR crystal may have been sufficient to induce
disordering of the very thin layer of the highly metastable ε-
form present.
The observed solid-state results postdissolution can also be
compared with those in a study by Priemel at al.,32 where, after
45 min of dissolution in stimulated intestinal fluid without
enzymes at pH 6.8 and temperature of 37 °C, the presence of
the α- and γ-polymorphs was confirmed with ATR-FTIR, for
both initially pure amorphous powders and samples stored for
5 days at the same storage conditions as in the present study
(30 °C/23% RH). It is possible that since their solid-state
analysis was performed at a later stage (45 min as opposed to
15 min in the present study), only the final prevailing
polymorphs were present. However, as mentioned above, our
results suggest that nonlinear imaging was more sensitive than
the ATR-FTIR and could allow detection of the ε-form when
ATR-FTIR or XRD may not.
The multimodal nonlinear imaging also provided other
solid-state-specific information on distribution at the tablet
surface that could not have been derived from the other
characterization techniques used. Tablet cracks observed on
days 1 and 2 with samples stored at 30 °C/23% RH upon
dissolution typically contained crystals, as indicated by a SFG
signal from these areas. Such surface irregularities or
imperfections are typically places where the dissolution process
is more rapid, which is why those areas are often referred to as
“high energy spots”. Interestingly, the “crack-specific” crystal-
lization was much less apparent in the samples stored at 30
°C/75% RH and may be due to a greater degree of relaxation
in these regions when stored at the higher humidity.
The sample presentation during storage also appears to
affect dissolution behavior. Priemel at el.32 reported that the
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dissolution behavior of amorphous indomethacin particles
stored at 30 °C/23% RH for 5 days was the same as that of the
reference γ-form. Their study involved intrinsic dissolution
experiments performed in simulated intestinal fluid without
enzymes at pH 6.8 and with 0.05% of Tween 20. Their
dissolution profiles corresponded to that of the γ-form already
after 5 days, whereas in the present study at the same storage
conditions, the dissolution profiles after 7 days approached
that of the γ-form but were essentially the same as the γ-form
only after 22 days of storage. In their study, individual particles
were stored unlike the compressed tablets in this study. The
greater overall surface area exposed to the environment during
the storage in the study by Priemel et al.32 may have affected
the subsequently prepared tablet surface crystallinity prior to
dissolution. This hypothesis could be tested with nonlinear
imaging in the future.
Finally, it is interesting to note that in most of the samples,
and in all those stored at higher humidity, multiple solid-state
forms were simultaneously observed postdissolution, including
two to four different polymorphs. This suggests that the
transitions do not necessarily include only sequential
transitions, as commonly reported with analytical techniques
less efficient at detecting minority species. It is likely that
heterogeneous sample characteristics (higher and lower energy
amorphous regions on the tablet surfaces induced by particle
compression into tablets) and dissolution conditions (different
flow dynamics and local solution concentrations induced by
surface roughness) contribute to this complex solid-state
behavior. It is, however, also possible that the samples are
exhibiting probabilistic crystallization behavior, in that more
than one solid-state crystalline form may simultaneously
crystallize in a single set of conditions.
5. CONCLUSIONS
Simultaneous CARS and SFG imaging has been performed to
elucidate complex solvent-mediated phase transformations on
amorphous tablet surfaces upon dissolution as a function of
storage time. SEM, XRD, and ATR-FTIR were used as
complementary methods. Overall, multimodal nonlinear
imaging proved to be more informative and sensitive than
the other techniques used, with distributions of indomethacin
polymorphs and the amorphous form efficiently imaged. In
particular, the multimodal nonlinear imaging was better able to
simultaneously detect multiple polymorphic forms, including
those present in trace amounts. SFG also revealed which of the
indomethacin polymorphs have noncentrosymmetric struc-
tures.
In particular, the recently reported ε-form of indomethacin
was observed to form only upon exposure of the amorphous
form to the dissolution media, in the early stages of storage at
both storage conditions. This form was further characterized
with XRD, Raman, and CARS and confirmed to have a
noncentrosymmetric structure according to SFG.
It has earlier been established that surface crystallinity is
generally more important than overall crystallinity when
considering the relationship between crystallinity and the
critical quality attribute, dissolution. Thus, multimodal non-
linear optical imaging is a suitable technique for understanding
this relationship, especially when developing amorphous drugs
and dosage forms. In this present study, very early stage
crystallization observed with nonlinear imaging, but not
detectable with the conventional solid-state analysis methods,
did not have a significant effect on dissolution behavior.
However, trace levels of crystallinity may be important in other
samples, and multimodal nonlinear optical imaging combined
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